News & Updates

A wearable chest patch device can continuously monitor vital signs in patients with the coronavirus disease 2019 (COVID-19), facilitating the early detection of cardiovascular deterioration, according to a recent study.

Individuals who are obese but without metabolic abnormalities (metabolically healthy obese [MHO]) have an elevated risk of developing MACE-HF*, new-onset heart failure (HF), and new-onset atrial fibrillation (AF), according to a French study presented at EASD 2021.

In patients with acute coronary syndrome (ACS) or stable angina pectoris (SAP), undergoing noncardiac surgery after stenting increases the risk of myocardial infarction (MI), but only when procedures are performed during acute admission, a recent study has found.

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

In individuals with type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide appeared to yield a cardioprotective benefit, data from the secondary endpoint analysis of the LIRAFLAME* trial suggests.

Cardiac manifestations, such as acute myocardial infarction (AMI) and myocarditis, after vaccination for the coronavirus disease 2019 (COVID-19) are more common in men, according to a recent Singapore study. AMI is more likely to arise after the first shot, while myocarditis becomes more common after the second dose.

Women on menopausal hormone therapy are at risk of developing hypertension, particularly those using oral oestrogen plus a progestogen such as pregnane and norpregnane derivatives, according to a study.